Introduction. The COVID-19 pandemic has stimulated the search for drugs with specific antiviral activity against the new pathogenic strain of the SARS-CoV-2 coronavirus. First of all, scientific search was aimed at studying drugs with already proven efficacy against influenza and ARVI.The aim of this workwas to study the antiviral activity of Cytovir®-3in vitroin relation to the cytopathogenic effect of the SARS-CoV-2 virus.Material and methods.The antiviral activity of the drug Cytovir®-3 against the SARS-CoV-2 virus was studied in experimental modelsin vitroon Vero CCL81 cell culture (ATCC). The maximum tolerated concentration and the 50% cytotoxic dose were determined using a quantitative microculture tetrazolium test assay to calculate the working range of the concentrations of the test drug.Results and discussion.As a result of the study, it was shown that the greatest activity of the drug was manifested when it was added to the cells 24 hours before and 1 hour and 24 hours after viral infection, the inhibition level reached 53% (>IC50) at the drug concentrations of 105, 55, and 85 µg/ml, respectively. Cytovir®-3 suppressed the viral activity of SARS-CoV-2 in the dose range from 10 µg/ml to 105 µg/ml under the indicated infection conditions. It was found that the drug did not exhibit cytotoxic effects on the Vero cell culture in the range of antiviral doses.Conclusion.The antiviral activity of Cytovir®-3 against the SARS-CoV-2 virus has been proven due to the achievement of IC50, which is below the maximum tolerated dose of 149 µg/ml.
30 August 2021 in Antibiot Khimioter = Antibiotics and Chemotherapy
On account of the COVID-19 pandemic, the global pharmaceutical industry has achieved impressive results in the development and introduction of various types of vaccines causing the formation of acquired immunity against the SARS-CoV-2 coronavirus into clinical practice. However, none of them currently show the declared one hundred percent guarantee of protection. In the case of the COVID-19 disease, patients with concomitant pathologies are the most vulnerable to the occurrence of severe complications. The aerosol route of transmission of SARS-CoV-2 contributes to the emergence of outbreaks of the new coronavirus infection in crowded places and closed rooms with poor ventilation. In this regard, an urgent problem is the search for drugs with local antiviral activity, which, together with restrictive measures and mask wearing policy, can potentially reduce the likelihood of contracting coronavirus. In this experimental in vitro study on Vero CCL81 cell culture (ATCC), the local antiviral activity of the drug Thymogen® spray against the SARS-CoV-2 virus was studied in comparison with the antiseptic Miramistin® solution. As a result of the experiment, no toxic effects on Vero cells were detected in the drugs in the studied concentrations. In a series of experiments, Thymogen® spray showed local antiviral activity against SARS-CoV-2 when the virus titer was 5,2 lg TCID50. Therefore, the drug Thymogen® dosed nasal spray has high potential as a topical drug for prevention and treatment of COVID-19 disease, which requires additional confirmation in relevant clinical studies.
20 June 2024 in Russian Journal of Evidence-Based Gastroenterology
Objective. To explore the preventive and healing impacts of orally administered alpha-glutamyl-tryptophan on gastric mucosa ulcerative lesions in rats. Material and methods. The research involved 110 male Wistar rats weighing 220±20 grams. We investigated the effects of the dipeptide alpha-glutamyl-tryptophan, administered at doses of 0.1 μg/kg and 10 μg/kg. As a comparison, we used sucralfate at a dose of 200 mg/kg. The study consisted of two sets of experiments designed to evaluate the preventative and healing effects of alpha-glutamyl-tryptophan on gastric ulcers caused by indomethacin. In addition, we analyzed the activity of superoxide dismutase (SOD) and the levels of the lipid peroxidation byproduct malondialdehyde (MDA) in the serum. Results. Preventive administration of alpha-glutamyl-tryptophan significantly mitigates the occurrence and severity of gastric ulcers, reducing ulcer frequency by up to 1.9—2.4-fold and mucosal damage by up to 2.7—3.1-fold. Additionally, there was an increase in SOD activity by up to 1.6—1.7-fold and a decrease in MDA levels, indicating reduced oxidative stress and emphasizing alpha-glutamyl-tryptophan’s antioxidant properties. Therapeutically, alpha-glutamyl-tryptophan administration post-ulcer induction led to reduction in both the number and size of gastric ulcers at a 10 μg/kg dosage—decreased by 1.5-fold and 2.7-fold, respectively, compared to indomethacin group. These results were comparable with sucralfate-treated group. Gastroprotective activity was also noted, as shown by 1.2-fold increased SOD activity and 1.5-fold decreased MDA levels. Conclusions. The findings demonstrate that alpha-glutamyl-tryptophan exhibits anti-ulcerative and antioxidant properties when administered in a prophylactic and therapeutic regimen within an indomethacin-induced model of ulceration.
Introduction. A comprehensive approach to treatment of chronic prostatitis, representing a widespread and poorly treatable disease, includes the use of antibacterial, anti-inflammatory medicines, etc. In this context, a promising approach to the treatment of chronic prostatitis involves the use of bioregulatory peptides isolated from bovine prostate tissue.Objective. To study the effect of cattle prostate extract containing bioregulatory peptides on the functional activity of lymphatic vessels.Маterials and methods. The study was performed on isolated lymphatic vessels of rats. The range of studied concentrations of the substance was 2–10 µg/ mL (in terms of water-soluble peptides).Results. Bioregulatory peptides included into the prostate extract impacts the vasomotor activity of lymphatic vessels. In the range of studied concentrations (2–10 µg/ml), the substance has a stimulating effect on lymphangion motility. This is realized by increasing the rate of lymphatic vessel contractions, which effect is most pronounced at the concentration of 5 µg/ml as a 37.6% (p ≤ 0.05) of base level. The obtained stimulating effect is stable during 30-min “washing” of lymphatic vessels with physiological solution.Conclusions. Water-soluble bioregulatory peptides contained in the extract of cattle prostate and having organotropic action on the prostate gland may contribute to the reduction of tissue edema by activating the motility of pelvic lymphatic vessels.
18 July 2023 in Antibiot Khimioter = Antibiotics and Chemotherapy
Introduction. The requirements of modern clinical guidelines for the treatment of respiratory viral infections suggest the possibility of identifying a specific viral pathogen. In this regard, the search for drugs with selective activity against respiratory syncytial virus and parainfluenza virus is relevant. The purpose of the work is to study the antiviral activity of the drug Cytovir®-3 in vitro in relation to the cytopathogenic effect of respiratory viruses (parainfluenza virus and respiratory syncytial virus). Material and methods. The antiviral effect of Cytovir®-3 in comparison with Umifenovir against parainfluenza virus and respiratory syncytial virus was studied on Vero cell culture. Drugs were administered 1 hour before (prophylactic regimen) and 1 hour after (treatment regimen) infection of the cell culture with respiratory viruses. The working range of concentrations of the studied drugs was calculated based on the values of 50% cytotoxic concentration calculated based on the results of a quantitative microtetrazole test. Results and discussion. The drug Cytovir®-3 in two schemes of application (therapeutic or prophylactic) showed its antiviral efficacy in vitro against respiratory syncytial virus and parainfluenza virus due in the non-toxic range (0–794 µg/ml). At the same time, the suppressive effect of the drug Cytovir®-3 against the parainfluenza virus begins at lower concentrations of the drug with its early (preventive) introduction into cell culture (250 mcg/ml). Conclusion. Antiviral activity of Cytovir®-3 has been proven in vitro against parainfluenza virus and respiratory syncytial virus. At the same time, in all series of experiments, Cytovir®-3 had a higher index of selectivity of antiviral action than that of the comparison drug Umifenovir.
16 January 2024 in Antibiot Khimioter = Antibiotics and Chemotherapy
Introduction. Due to the ability of the influenza virus to mutate, it is necessary to constantly search for new drugs with preventive and direct antiviral effects.The aim of the study is to investigate the protective antiviral properties of the drug Thymogen®, a dosed nasal spray, on a model of lethal influenza pneumonia in laboratory animals.Material and methods. White mature mice were selected for the experiment on the antiviral activity of the tested drug samples against H1N1 influenza virus; the mice were divided into the following groups (30 animals each): two negative control groups; two groups receiving Thymogen®, a dosed nasal spray (before and after infection); one group of animals received Tamiflu®, and one received Hexoral®. The mortality of animals with influenza pneumonia was assessed; histological and morphometric analyses were also carried out.Results and discussion. The morphological picture of the lungs of animals correlated with their protective activity when analyzing the survival of animals. The normalization of tissue structure was pronounced the most in the group of animals infected with the virus, pre-incubated with Thymogen®, a dosed nasal spray, and in the group receiving Tamiflu®. Moreover, the viral load in the lungs was lower by 1.5 and 1.2 orders of magnitude in the group receiving Thymogen®, dosed nasal spray, compared to the negative control group (the 3rd and the 6th days of the experiment, respectively), which corresponds to a decrease in the intensity of viral reproduction by 31.6 and 15.8 times